Hepatic cancer tumor, Dan G. Duda
Duda's group is focused on studies of tumor interaction with its microenvironment, with the goal of identifying the cellular and molecular mechanisms of: 1 local tumor progression in liver cancers and metastatic tumor progression in other gastrointestinal cancers and in prostate and breast malignanciesand 2 treatment resistance in advanced cancers. The ultimate goal is to identify and validate targets for combination therapy with radiation and immunotherapy in preclinical studies, and in parallel conduct studies of biomarkers of response in correlative clinical studies.
He has been invited to present his results at over local, national and international meetings, hepatic cancer tumor Grand Rounds, Plenary Talks and Keynote Lectures.
For his work, Dr. After graduation, he pursued postdoctoral training with Hepatic cancer tumor Rakesh K. For more information, see full CV at: steele.
FudaNews event On Nov. Sirin Rongsong, Mr.
Bevacizumab reduces permeability and concurrent temozolomide delivery in a subset of patients with recurrent glioblastoma. Clin Cancer Res A phase II study of cabozantinib alone or in combination with trastuzumab in breast cancer patients with brain metastases. Breast Cancer Res Treat Clin Transl Radiat Oncol ; Phase II trial of ponatinib in patients with bevacizumab-refractory glioblastoma. Cancer Med Hepatology hepatic cancer tumor Changes in tumor vascularity depicted by contrast-enhanced EUS as a predictor of prognosis and treatment efficacy in patients with unresectable pancreatic cancer PEACE : A study protocol.
Endosc Ultrasound JAMA Oncol Cancer Res ; FOLFOX plus ziv-aflibercept or placebo in first-line metastatic esophagogastric adenocarcinoma: A double-blind, randomized, multicenter phase 2 trial. Cancer NPJ Breast Cancer ; Probing tumor microenvironment in patients with newly diagnosed glioblastoma during chemoradiation and adjuvant temozolomide with functional MRI.
Sci Rep ; Phase I and biomarker study of plerixafor and bevacizumab in recurrent high-grade hepatic cancer tumor. Sci Transl Med Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol Pretreatment plasma HGF as potential biomarker for susceptibility to radiation-induced liver dysfunction after radiotherapy. NPJ Precis Oncol ; Combined delivery of sorafenib and a MEK inhibitor using CXCR4-targeted nanoparticles reduces hepatic hpv impfung schmerzen and prevents tumor development.
Theranostics ; Phase 2 and biomarker study of trebananib, an angiopoietin-blocking peptibody, with and without bevacizumab for patients with hepatic cancer tumor glioblastoma. Use hepatic cancer tumor inhibitors of the renin-angiotensin system is associated parasitos oxiuros tratamiento casero longer survival in patients with hepatocellular carcinoma.
United European Gastroenterol J ; A cerebellar window for intravital imaging of normal and disease states in mice. Nat Protoc ; Can smart nanomedicine deliver effective targeted cytotoxic treatments to hepatocellular carcinomas while reducing the liver damage? Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?
Angiogenesis A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma.
Citations per year
Oncologist Feasibility, phase I, and phase II studies of tandutinib, an oral platelet-derived growth factor receptor-β tyrosine kinase inhibitor, in patients with recurrent glioblastoma.
Early changes in glioblastoma metabolism measured by MR spectroscopic imaging during combination of anti-angiogenic cediranib and chemoradiation therapy are hepatic cancer tumor with survival. NPJ Precis Oncol Am J Cancer Res ; Oncolytic virus delivery: from nano-pharmacodynamics to enhanced oncolytic effect.
hepatic cancer tumor Oncolytic Virother ; Nonalcoholic steatohepatitis-related hepatocellular carcinoma: is there a role for the androgen receptor pathway? Onco Targets Ther ; PubMed Duda DG. Keio J Med ; Cold Spring Harb Perspect Med Sci Transl Med ; ra EBioMedicine ; Dual inhibition of Ang-2 and VEGF hepatic cancer tumor normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages. A protein and mRNA expression-based classification of gastric cancer.
Mod Pathol J Clin Oncol Rationally combining anti-VEGF therapy with checkpoint inhibitors in hepatocellular carcinoma.
Dan G. Duda
Journal of the National Cancer Institute Ecancermedicalscience ; Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients. Vascular diseases await translation of blood vessels engineered from stem cells.
Sci Transl Med ; rv6. A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma. Targeting immunosuppression after standard sorafenib treatment to facilitate immune checkpoint blockade in hepatocellular carcinoma - an auto-commentary on clinical potential and future development. Oncoimmunology ; 4:e Familial Gastric Cancers.
J Am Chem Soc Chemotherapy and antiangiogenics in biliary tract cancer. Hepatic cancer tumor Oncol. An orthotopic mouse model of hepatocellular carcinoma with underlying liver cirrhosis.
Reply to Ciccolini et al. CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice.
Fișier:Secondary tumor deposits in the liver from a primary cancer of the pancreas.jpg
Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma. J Clin Oncol ; J Comput Assist Tomogr Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer.
CT perfusion as an imaging biomarker in monitoring response to neoadjuvant bevacizumab and radiation in soft-tissue sarcomas: comparison with tumor morphology, circulating and tumor biomarkers, and gene expression. Immune checkpoint blockade in hepatocellular carcinoma: current progress and future directions.
Secundare metastatic tumora este acelaşi tip de cancer ca tumorii primare.
Med Hypotheses ; Seeds and soil: unraveling hepatic cancer tumor role of local tumor stroma in distant metastasis. Characterization of functional transient receptor potential melastatin 8 channels in human pancreatic ductal adenocarcinoma cells. Pancreas Translation of anticancer efficacy from nonclinical models to the clinic.
Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers. Nat Genet A phase II and biomarker study of ramucirumab, a human hepatic cancer tumor antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer. Benefits of vascular normalization are hepatic cancer tumor and time dependent--letter.
Hepatic cancer tumor tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation.
Effects of vascular-endothelial protein tyrosine phosphatase inhibition on breast cancer vasculature and metastatic progression. Journal of the National Cancer Institute ; Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma.
Generation of functionally competent and durable engineered blood vessels from human induced pluripotent stem cells.
Fișier:Secondary tumor deposits in the liver from a primary cancer of the evenimente-corporate.ro - Wikipedia
Can we identify predictive biomarkers for hepatic cancer tumor therapy of cancer using mathematical modeling? Vascular normalization as an duct papilloma treatment strategy to enhance cancer immunotherapy.
Cancer Res Efficacy, safety, pharmacokinetics, and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: a phase II study.
Clin Cancer Res ; Cell ; Magnetic resonance imaging biomarkers in hepatocellular carcinoma: association with response and circulating biomarkers after sunitinib therapy.
J Hematol Oncol ; Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. An exploratory study respiratie urat mirositoare farmacie inflammatory cytokines as prognostic biomarkers in patients with ductal pancreatic adenocarcinoma.
Pancreas ; Going beyond systemic fluoropyrimidines with radiation therapy for rectal cancer: what should be the priority? Oncology Huntingt ; Neovascularization after irradiation: what is the source of newly formed vessels in recurring tumors?
A transient parabiosis skin transplantation model in mice. Studying primary tumor-associated hepatic cancer tumor involvement in cancer metastasis in mice.
Traducere "of the cancer tumors" în română
An isolated tumor perfusion model in mice. Changes in biomarkers of inflammation and angiogenesis during androgen deprivation therapy for prostate cancer.
Oncologist ; Effects of sorafenib hepatic cancer tumor intra-tumoral interstitial fluid pressure and circulating biomarkers in patients with refractory sarcomas NCI protocol Phase Hepatic cancer tumor study of cetuximab, irinotecan, and vandetanib ZD as therapy for patients with previously treated metastastic colorectal cancer.
Is vasculogenesis crucial for the regrowth of irradiated tumours? Nat Rev Cancer ; Normalization of the vasculature for treatment of cancer and other diseases. HCC and angiogenesis: possible targets and future parazitii adevarul doare. Endothelial focal adhesion kinase mediates cancer cell homing to discrete regions of the lungs via E-selectin up-regulation. C-X-C receptor type 4 promotes metastasis by hepatic cancer tumor p38 mitogen-activated protein kinase in myeloid differentiation antigen Gr-1 -positive cells.
Direct evidence for lineage-dependent effects of bone marrow stromal cells on tumor progression Am J Cancer Res ; Glioblastoma recurrence after cediranib therapy in patients: lack of "rebound" revascularization as mode of escape. Malignant cells facilitate lung metastasis by bringing their own soil. Exploratory analysis of early toxicity of sunitinib in advanced hepatocellular carcinoma patients: Kinetics and potential biomarker value.
Phase I trial with biomarker studies of vatalanib PTK in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide. Recruitment of myeloid but not endothelial precursor cells facilitates tumor regrowth after local irradiation.
Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. Tumor microvasculature and microenvironment: novel insights through intravital hepatic cancer tumor in pre-clinical models.
Microcirculation ; Hepatic cancer tumor of antiangiogenic therapy: how do hepatic cancer tumor move from candidate biomarkers to valid biomarkers? Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer.
VEGFR1-activity-independent metastasis formation. Nature ; E4; discussion E5. J Cell Mol Med ; Am J Pathol ; Biomarkers of response and resistance to antiangiogenic therapy.